Janux Therapeutics Doses First Patient In The Phase 1 Clinical Trial For JANX013, Its PSMA-Targeted Tumor-Activated CD28 Co-Stimulatory Bispecific, In Patients With Metastatic Castration-Resistant Prostate Cancer

Loading news article.

Janux Therapeutics Doses First Patient In The Phase 1 Clinical Trial For JANX013, Its PSMA-Targeted Tumor-Activated CD28 Co-Stimulatory Bispecific, In Patients With Metastatic Castration-Resistant Prostate Cancer | WAPE

Janux Therapeutics Doses First Patient In The Phase 1 Clinical Trial For JANX013, Its PSMA-Targeted Tumor-Activated CD28 Co-Stimulatory Bispecific, In Patients With Metastatic Castration-Resistant Prostate Cancer

Article summary

Related companies

Comments —